Bain Capital Life Sciences Investors
Latest statistics and disclosures from Bain Capital Life Sciences Investors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are NUVL, PHVS, NAMS, SWTX, IRON, and represent 55.36% of Bain Capital Life Sciences Investors's stock portfolio.
- Added to shares of these 2 stocks: TNGX (+$11M), SVRA (+$9.9M).
- Reduced shares in these 7 stocks: CRNX (-$31M), Cymabay Therapeutics (-$24M), DVAX (-$22M), THRD, PHVS, CARA, IRON.
- Sold out of its position in THRD.
- Bain Capital Life Sciences Investors was a net seller of stock by $-62M.
- Bain Capital Life Sciences Investors has $894M in assets under management (AUM), dropping by -7.91%.
- Central Index Key (CIK): 0001703031
Tip: Access up to 7 years of quarterly data
Positions held by Bain Capital Life Sciences Investors consolidated in one spreadsheet with up to 7 years of data
Download as csv Download as ExcelPortfolio Holdings for Bain Capital Life Sciences Investors
Bain Capital Life Sciences Investors holds 31 positions in its portfolio as reported in the September 2023 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
---|---|---|---|---|---|---|
Nuvalent Inc-a (NUVL) | 18.4 | $164M | 3.6M | 45.97 |
|
|
Pharvaris N V (PHVS) | 11.2 | $100M | 4.8M | 20.87 |
|
|
Newamsterdam Pharma Company Ordinary Shares (NAMS) | 10.8 | $97M | 11M | 9.25 |
|
|
Springworks Therapeutics (SWTX) | 8.0 | $71M | 3.1M | 23.12 |
|
|
Disc Medicine (IRON) | 7.0 | $63M | 1.3M | 46.98 |
|
|
Savara (SVRA) | 6.0 | $54M | +22% | 14M | 3.78 |
|
Crinetics Pharmaceuticals In (CRNX) | 4.2 | $38M | -44% | 1.3M | 29.74 |
|
Tango Therapeutics (TNGX) | 3.6 | $33M | +50% | 2.9M | 11.26 |
|
Natera (NTRA) | 3.5 | $31M | 700k | 44.25 |
|
|
Cabaletta Bio (CABA) | 3.4 | $30M | 2.0M | 15.22 |
|
|
Aclaris Therapeutics (ACRS) | 2.6 | $23M | 3.4M | 6.85 |
|
|
Eqrx | 2.5 | $22M | 10M | 2.22 |
|
|
X4 Pharmaceuticals (XFOR) | 1.9 | $17M | 16M | 1.09 |
|
|
Arcutis Biotherapeutics (ARQT) | 1.8 | $16M | 3.0M | 5.31 |
|
|
Nurix Therapeutics (NRIX) | 1.6 | $14M | 1.8M | 7.86 |
|
|
Cymabay Therapeutics | 1.5 | $14M | -63% | 914k | 14.91 |
|
Dynavax Technologies Corp Com New (DVAX) | 1.5 | $14M | -62% | 915k | 14.77 |
|
Annexon (ANNX) | 1.5 | $14M | 5.7M | 2.36 |
|
|
Marinus Pharmaceuticals Com New (MRNS) | 1.3 | $12M | 1.4M | 8.05 |
|
|
Mersana Therapeutics (MRSN) | 1.2 | $11M | 8.7M | 1.27 |
|
|
Rapid Micro Biosystems Class A Com (RPID) | 1.0 | $9.1M | 8.4M | 1.08 |
|
|
Syros Pharmaceuticals Com New (SYRS) | 0.9 | $8.4M | 2.1M | 3.95 |
|
|
Solid Biosciences Com New (SLDB) | 0.9 | $7.9M | 3.1M | 2.52 |
|
|
Atea Pharmaceuticals (AVIR) | 0.8 | $7.5M | 2.5M | 3.00 |
|
|
Nautilus Biotechnology (NAUT) | 0.7 | $6.3M | 2.0M | 3.16 |
|
|
Xilio Therapeutics (XLO) | 0.7 | $5.9M | 2.8M | 2.11 |
|
|
2seventy Bio Common Stock (TSVT) | 0.6 | $5.5M | 1.4M | 3.92 |
|
|
Adagio Therapeutics (IVVD) | 0.4 | $3.3M | 1.9M | 1.70 |
|
|
C4 Therapeutics Com Stk (CCCC) | 0.3 | $3.1M | 1.6M | 1.86 |
|
|
Newamsterdam Pharma Company *w Exp 11/22/202 (NAMSW) | 0.0 | $190k | 100k | 1.90 |
|
|
Cara Therapeutics (CARA) | 0.0 | $40k | -97% | 24k | 1.68 |
|
Past Filings by Bain Capital Life Sciences Investors
SEC 13F filings are viewable for Bain Capital Life Sciences Investors going back to 2017
- Bain Capital Life Sciences Investors 2023 Q3 filed Nov. 14, 2023
- Bain Capital Life Sciences Investors 2023 Q2 filed Aug. 14, 2023
- Bain Capital Life Sciences Investors 2023 Q1 filed May 15, 2023
- Bain Capital Life Sciences Investors 2022 Q4 filed Feb. 14, 2023
- Bain Capital Life Sciences Investors 2022 Q3 filed Nov. 14, 2022
- Bain Capital Life Sciences Investors 2022 Q2 filed Aug. 15, 2022
- Bain Capital Life Sciences Investors 2022 Q1 filed May 16, 2022
- Bain Capital Life Sciences Investors 2021 Q4 filed Feb. 14, 2022
- Bain Capital Life Sciences Investors 2021 Q3 filed Nov. 15, 2021
- Bain Capital Life Sciences Investors 2021 Q2 filed Aug. 16, 2021
- Bain Capital Life Sciences Investors 2021 Q1 filed May 17, 2021
- Bain Capital Life Sciences Investors 2020 Q4 filed Feb. 16, 2021
- Bain Capital Life Sciences Investors 2020 Q3 filed Nov. 16, 2020
- Bain Capital Life Sciences Investors 2020 Q2 filed Aug. 14, 2020
- Bain Capital Life Sciences Investors 2020 Q1 filed May 15, 2020
- Bain Capital Life Sciences Investors 2019 Q4 filed Feb. 14, 2020